Literature DB >> 28887401

Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Steven P Rowe1,2, Kenneth J Pienta2, Martin G Pomper3,2, Michael A Gorin3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28887401      PMCID： PMC6910634          DOI： 10.2967/jnumed.117.195255

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   10.057


× No keyword cloud information.
  51 in total

1.  Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT.

Authors:  C Artigas; J Alexiou; C Garcia; Z Wimana; F-X Otte; T Gil; R Van Velthoven; P Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-27       Impact factor: 9.236

2.  Follicular Lymphoma Showing Avid Uptake on 68Ga PSMA-HBED-CC PET/CT.

Authors:  Gowri L Kanthan; Luke Coyle; Andrew Kneebone; Geoffrey Paul Schembri; Edward Hsiao
Journal:  Clin Nucl Med       Date:  2016-06       Impact factor: 7.794

3.  68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.

Authors:  Wolfgang P Fendler; Matthias Eiber; Mohsen Beheshti; Jamshed Bomanji; Francesco Ceci; Steven Cho; Frederik Giesel; Uwe Haberkorn; Thomas A Hope; Klaus Kopka; Bernd J Krause; Felix M Mottaghy; Heiko Schöder; John Sunderland; Simon Wan; Hans-Jürgen Wester; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

4.  Aspecific Uptake of 68GA-PSMA in Paget Disease of the Bone.

Authors:  Sophie Bourgeois; Pieterjan Gykiere; Lode Goethals; Hendrik Everaert; Frank W De Geeter
Journal:  Clin Nucl Med       Date:  2016-11       Impact factor: 7.794

5.  Multitracer Molecular Imaging of Paget Disease Targeting Bone Remodeling, Fatty Acid Metabolism, and PSMA Expression on PET/CT.

Authors:  Thorsten Derlin; Desiree Weiberg; Jan M Sohns
Journal:  Clin Nucl Med       Date:  2016-12       Impact factor: 7.794

6.  BI-RADS categorization as a predictor of malignancy.

Authors:  S G Orel; N Kay; C Reynolds; D C Sullivan
Journal:  Radiology       Date:  1999-06       Impact factor: 11.105

7.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

8.  PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2.

Authors:  Jeffrey C Weinreb; Jelle O Barentsz; Peter L Choyke; Francois Cornud; Masoom A Haider; Katarzyna J Macura; Daniel Margolis; Mitchell D Schnall; Faina Shtern; Clare M Tempany; Harriet C Thoeny; Sadna Verma
Journal:  Eur Urol       Date:  2015-10-01       Impact factor: 20.096

9.  68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases.

Authors:  Ingo Einspieler; Robert Tauber; Tobias Maurer; Markus Schwaiger; Matthias Eiber
Journal:  Clin Nucl Med       Date:  2016-05       Impact factor: 7.794

10.  Rectal Carcinoma on 68Ga-PSMA PET/CT.

Authors:  Yi-Tung Tom Huang; William Fong; Paul Thomas
Journal:  Clin Nucl Med       Date:  2016-03       Impact factor: 7.794
View more
  40 in total

Review 1.  Metaanalysis of 68Ga-PSMA-11 PET Accuracy for the Detection of Prostate Cancer Validated by Histopathology.

Authors:  Thomas A Hope; Jeremy Z Goodman; Isabel E Allen; Jeremie Calais; Wolfgang P Fendler; Peter R Carroll
Journal:  J Nucl Med       Date:  2018-12-07       Impact factor: 10.057

2.  Novel Structured Reporting Systems for Theranostic Radiotracers.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Stefano Fanti; Mehrbod S Javadi; Takahiro Higuchi; Alexander Weich; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Ken Herrmann; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2019-02-22       Impact factor: 10.057

3.  PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  Eur Urol       Date:  2017-11-11       Impact factor: 20.096

4.  Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Jeffrey P Leal; Takahiro Higuchi; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

5.  Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Authors:  Yafu Yin; Rudolf A Werner; Takahiro Higuchi; Constantin Lapa; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

Review 6.  Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.

Authors:  Thomas A Hope; Ali Afshar-Oromieh; Matthias Eiber; Louise Emmett; Wolfgang P Fendler; Courtney Lawhn-Heath; Steven P Rowe
Journal:  AJR Am J Roentgenol       Date:  2018-06-27       Impact factor: 3.959

7.  Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.

Authors:  Erin Gomez; Phuoc T Tran; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Clin Nucl Med       Date:  2019-04       Impact factor: 7.794

8.  Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation.

Authors:  Evyn G Arnfield; Paul A Thomas; Matthew J Roberts; Anita M Pelecanos; Stuart C Ramsay; Charles Y Lin; Melissa J Latter; Peter L Garcia; David A Pattison
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-16       Impact factor: 9.236

9.  68Ga-PSMA I&T PET/CT for primary staging of prostate cancer.

Authors:  Wojciech Cytawa; Anna Katharina Seitz; Stefan Kircher; Kazuhito Fukushima; Johannes Tran-Gia; Andreas Schirbel; Tomasz Bandurski; Piotr Lass; Markus Krebs; Wojciech Połom; Marcin Matuszewski; Hans-Jürgen Wester; Andreas K Buck; Hubert Kübler; Constantin Lapa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-16       Impact factor: 9.236

10.  Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Xin Li; Bruce J Trock; Rudolf A Werner; Sarah Frey; Michael DiGianvittorio; J Keith Bleiler; Diane K Reyes; Rehab Abdallah; Kenneth J Pienta; Michael A Gorin; Martin G Pomper
Journal:  J Nucl Med       Date:  2019-08-26       Impact factor: 10.057
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.